This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

IRVING H. LEOPOLD, M.D.; THOMAS R. HEDGES, Jr., M.D.; JEROME MONTANA, M.D.; NARENDRA KRISHNA, M.D.; SYBIL BECKETT

AMA Arch Ophthalmol. 1960;63(3):544-547.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Myasthenia gravis, a disease characterized by paralysis of skeletal muscles, is of considerable ophthalmologic interest because the initial symptoms usually are found in the extraocular muscles and, in the late stages of the disease, practically all patients show involvement of the extraocular muscles. The ophthalmologist is one of the first to encounter the evidences of this disease and must therefore be familiar with the means of differential diagnosis and therapy.

Diagnosis is usually established in a suspected case by finding dramatic improvement following the subcutaneous injection of neostigmine or the intravenous injection of edrophonium (Tensilon). Aggravation of symptoms may occur with the administration of quinine or curare. Quinine and curare are usually utilized only if the results of tests with neostigmine or edrophonium are inconclusive.

Therapy of this condition, once the diagnosis has been established, is largely dependent upon the use of neostigmine (Prostigmin). The dosage which is required usually . . . [Full Text PDF of this Article]

Author Affiliations
Philadelphia

From the Graduate School of Medicine of the University of Pennsylvania and Wills Eye Hospital.

Footnotes
Submitted for publication Nov. 4, 1959.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?